Accolade Inc
NASDAQ:ACCD
Accolade Inc
Accounts Receivables
Accolade Inc
Accounts Receivables Peer Comparison
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Accolade Inc
NASDAQ:ACCD
|
Accounts Receivables
$26.7m
|
CAGR 3-Years
181%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
DaVita Inc
NYSE:DVA
|
Accounts Receivables
$2.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
5%
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Accounts Receivables
$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
CVS Health Corp
NYSE:CVS
|
Accounts Receivables
$10.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
2%
|
|
Cigna Corp
NYSE:CI
|
Accounts Receivables
$20.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Accounts Receivables
$2.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
10%
|
See Also
What is Accolade Inc's Accounts Receivables?
Accounts Receivables
26.7m
USD
Based on the financial report for Feb 28, 2023, Accolade Inc's Accounts Receivables amounts to 26.7m USD.
What is Accolade Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
31%
Over the last year, the Accounts Receivables growth was -13%. The average annual Accounts Receivables growth rates for Accolade Inc have been 181% over the past three years , 31% over the past five years .